Related Experiment Video

Updated: May 31, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Nicousamide blocks the effects of advanced glycation end products on renal cells

Hongyan Li1, Yi Zhang, Hongbo Wang

  • 1Department of pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. lhy2116@gmail.com

European Journal of Pharmacology
|July 19, 2011
PubMed

Insights

Nicousamide, a novel drug, effectively treats diabetic nephropathy by inhibiting advanced glycation end products (AGE). It prevents kidney cell damage and preserves renal function in this condition.

Area of Science:

  • Nephrology
  • Pharmacology
  • Cell Biology

Background:

  • Advanced glycation end products (AGE) are implicated in diabetic nephropathy pathogenesis.
  • AGEs stimulate fibrogenic factors like transforming growth factor-beta 1 (TGF-β1) and connective tissue growth factor (CTGF), leading to kidney damage.
  • These factors contribute to renal hypertrophy, sclerosis, and functional decline.

Purpose of the Study:

  • To investigate the therapeutic potential of nicousamide, a coumarin-aspirin derivative, against diabetic nephropathy.
  • To evaluate nicousamide's effects on AGE-induced cellular changes in a renal cell model.

Main Methods:

  • Utilized a renal mesangial and tubular epithelia cell model.
  • Employed Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Enzyme-Linked Immunosorbent Assay (ELISA) to analyze gene and protein expression.
  • Assessed cell cycle progression using flow cytometry.
  • Measured matrix metalloproteinase (MMP) activity.

Main Results:

  • Nicousamide significantly inhibited AGE-induced expression of TGF-β1 and CTGF.
  • The compound blocked AGE-induced G1-arrest in both mesangial and tubular epithelial cells.
  • Nicousamide restored matrix metalloproteinase activity suppressed by AGEs.

Conclusions:

  • Nicousamide demonstrates a protective effect against diabetic nephropathy.
  • The drug functions by counteracting the detrimental effects of AGEs on renal cells.
  • Nicousamide shows promise in retarding the progression of diabetic nephropathy.

More Related Videos

Preparation of Naringenin Solution for In Vivo Application08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...